Table I.

Clinical features of the patients with PLS.

Case	Age	Gender	Haemoglobin		Total bilirubin		Haemolysis	IS pre-PLS treatment	Treatment PLS
			Day of min. level	(g/dL)	Day of max level	(mg/dL)			RBC (ABO Rh)	IS
1	40	Male	18	6.6	17	49.15	Yes	CS + CSA	4 (0+)	nd
2	52	Male	29	7.9	36	6.87	Yes	CS + CSA	2 (0+)	CS
3	57	Male	15	6.6	13	11.46	Yes	CS + TAC	6 (B+)#	CS
4*	49	Male	16	6.4	14	4.80	Yes	CS + CSA + MMF	4 (A−)	CS
5	17	Female	13	3.4	13	8.20	Yes	CS + TAC	8 (0−)	CS
6	42	Male	11	5.0	11	4.79	Yes	CS + CSA	1 (AB+)#, 2 (0−), 1 (0+)	CS
7	45	Male	15	8.1	10	10.55	Yes	CS + CSA + MMF	2 (0−)	nd
8	49	Male	31	6.8	19	3.10	Yes	CS + MMF + TAC	4 (0+)	CS
9	48	Male	10	6.8	10	5.50	Yes	CS + MMF + TAC	1 (A+)#, 1 (0+)	nd
10	41	Female	12	7.9	12	2.95	Yes	CS + TAC	2 (0+)	CS
11	49	Male	12	6.8	11	4.34	Yes	CS + CSA + MMF	4 (0−)	CS
12	41	Female	56	6.8	59	2.77	Yes	CSA + MMF	4 (0−)	No

PLS: Passenger lymphocyte syndrome; IS: immunosuppression; RBC: red blood cell; CS: corticosteroids; CSA: cyclosporine A; MMF: mycophenolate mofetil; TAC: tacrolimus; nd: no data available;

^*CSA was decreased, because of renal toxicity, from 400 mg/12 h to 200 mg/12 h and MMF was added at a dose of 1,000 mg/12 h.

^#Transfusions of donor incompatible RBC.